We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.50 | 0.65% | 385.00 | 380.00 | 390.00 | 385.00 | 385.00 | 385.00 | 1,292 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 41.93M | 6.49M | 0.1361 | 28.29 | 182.42M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/2/2024 07:56 | The Board is recommending an interim dividend of 5.24 pence (2022: 2.62 pence) to be paid on 12 April 2024. The associated ex-dividend date will be 21 March 2024 with a record date of 22 March 2024. | zimbtrader | |
26/2/2024 07:53 | Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces its interim results for the six months to 31 December 2023, exceeding internal growth targets by delivering 20% revenue growth and 44% growth in pre-tax profits | zimbtrader | |
26/2/2024 07:51 | Anyone seen the results this morning. Seems ADVFN are rushing to link them on news. | zimbtrader | |
31/1/2024 21:55 | The main backers are French. It sells outside the US in various locations - including the UK. It markets itself very aggressively as a superior product to Tristel. I continue to believe that Tristel needs to develop a response, based upon scientific evidence. | james188 | |
31/1/2024 20:49 | Surely you can't shine a light into curved tube? I'm not at all sure that going on the offensive would do anything other than giving the competitor some free publicity. james188, how come it is selling products if it doesn't have FDA approval? apad | apad | |
31/1/2024 20:27 | This is not new. The lead product is Chronos - developed by Germitec. It is well financed and has been seeking FDA approval for over one year. I consider it a more significant potential threat than Trophon. I specifically raised this point with the company at the results presentation last Autumn. I was told that there are material problems with the product and that TSTL is relaxed about the threat and viewed the very direct attack it makes as a compliment. My response was that the company needs to go on the offensive and point out why it has the superior product. | james188 | |
31/1/2024 17:52 | Interesting. UV light has been around for ages as a disinfectant. I wonder what is special about this and whether UV disinfects crevices. apad | apad | |
31/1/2024 17:06 | OMG ... UV Smart D45. High level disinfection of ultrasound probes using UV-C light. Automated. Fast. No Consumables. Designed for healthcare teams prioritizing patient safety and workflow efficiency, the UV Smart D45 provides fast, automated, and traceable disinfection for ultrasound probes. Its instant high-level disinfection process, free from consumables, helps mitigate the risk of infections, including STDs and HPV spread, ensuring both infection control and sustainability. | piedro | |
23/1/2024 10:29 | Very volatile share.....that's one hell of a gap up. | 11_percent | |
23/1/2024 09:14 | Thumbs up from Canada | petewy | |
21/1/2024 13:06 | Good article by Richard Beddard for ii. hxxps://www.ii.co.uk | petewy | |
11/1/2024 16:25 | Well spotted petewy, I suppose there is no reason a share deal needs to be an open market transaction? | wad collector | |
11/1/2024 07:11 | Paul swinney from memory has sold 50% over the last number years with yesterday included. Let’s not forget he his approaching retirement most would be doing the same. | best1467 | |
10/1/2024 18:35 | Which suggests that the sales by Mr and Mrs Swinney had a prearranged buyer - probably an institution. The share is still relatively illiquid and hard to trade at material levels.We should know more about how things are progressing next month. Until then , I am adding when the share price dips. | james188 | |
10/1/2024 17:53 | someone bought 90,000at 4.36pm at 4.23 | petewy | |
10/1/2024 17:37 | Not sure anyone can confidently give the reason they sold other than themselves , but it was never going to be a vote of confidence in the share's prospects. Similarly it is not possible to interpret reasons for retirement without inside knowledge, it is often multifactorial. Suspect the share price will recover! | wad collector | |
10/1/2024 16:55 | I think he hung on to see the US approval through which was always us going to take longer than the market expected. I didn't realise he was married to Liz Dixon and today they sold 90,000 shares no doubt to fund retirement and market rewarded them with 9% drop in share price | gopher | |
10/1/2024 16:51 | TSTL director sales at 422.5p pushed the price down from 450p to 410p. Paul Swinney 50,000 sold 262,350 remaining. Liz Dixon 40,000 sold 229,000 remaining. apad | apad | |
05/1/2024 07:20 | My Portfolio: Year In Review 2023 I recap how each of my shares performed during 2023, including System1, Tristel, Bioventix and Mountview Estates. 02 January 2024 By Maynard Paton 2) Tristel (TSTL) "... December’s AGM also announced TSTL’s long-time chief exec is to retire this year. Deciding to retire when the exciting US potential all lies ahead may seem odd, but I believe TSTL’s ambition to become a “global market leader” demands skills beyond the present board given the protracted FDA saga. I would not be surprised if the finance director, who is married to the chief exec, decides to leave as well. A pair of US healthcare executives could be welcome replacements. ... - well said Maynard. | piedro | |
22/12/2023 17:44 | The organic growth will be by sales in North America. The only cash needed now is inventory and sales expertise. Unless there are other products being developed. | paulisi | |
20/12/2023 07:08 | I hope that the cash is primarily used to accelerate organic growth (not acquisitions). That is also what I expect will happen. | james188 | |
19/12/2023 12:00 | The new CEO will have to work out what to do with all the cash.Aquisition/spec | paulisi | |
19/12/2023 08:03 | ... The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates. ... will they try and keep it within the 'family'? ---------- FWIW, from the AGM of 11/12/2018 "On behalf of my Board colleagues I would like to thank Francisco Soler, who steps down today after 25 years, for his many years of service to the Company, and to honour him with the title of Lifetime President. Francisco co-founded the business with Paul Swinney in 1993. ---------- | piedro | |
19/12/2023 07:41 | CEO succession planning In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. ... ... ... | piedro |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions